Bower H et al. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol 2016;34(24):2851-7. Abstract

Cortes J et al. Ponatinib efficacy and safety in heavily pretreated leukemia patients: 3-year results of the PACE trial. EHA 2021;Abstract 100486.

Cortes J et al. Final 5-year study results of DASISION: The dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016;34(20):2333-40. Abstract

Hochhaus A et al. Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors. ASH 2020;Abstract LBA-4.

Hochhaus A et al.Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med 2017;376(10):917-27. Abstract

Hughes T et al. Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure. N Engl J Med 2019;381(24):2315-26. Abstract

Rea D et al. Asciminib, a specific allosteric BCR-ABL1 inhibitor, in patients with chronic myeloid leukemia carrying the T315I mutation in a phase 1 trial. Blood 2018;132(1):792. Abstract

Saussele S et al. Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: Results of the randomized CML study IV. Blood 2015;126(1):42-9. Abstract

Soverini S et al. BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Recommendations from an expert panel on behalf of European LeukemiaNet. Blood 2011;118(5):1208-15. Abstract